ArticleJournal of inflammation research2025
Chronic Inflammation in Patients with Chronic Coronary Syndrome Who Have Been Taking Lipid-Lowering Drugs as a Residual Risk Factor - a Bidirectional Synergistic Correlation with Epicardial Adipose Tissue.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association and impact of inflammatory markers and cardiac structure on atrial fibrillation risk: a study integrating NHANES with real-world data.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with coronary heart disease on long-term lipid-lowering agents typically maintain relatively low lipid levels. However, an elevated systemic inflammatory state represents another major risk factor for poor prognosis in these individuals. This study aims to investigate the relationship between systemic inflammation and adverse outcomes in patients with chronic coronary syndrome(CCS), as well as its synergistic interaction with epicardial adipose tissue (EAT). Methods: This is a double-center retrospective cohort study. From March 2017 to September 2023, We retrospectively included 278 patients with CCS from two medical institutions in China, all of whom had been receiving long-term statin therapy. Participants underwent cardiovascular magnetic resonance (CMR) imaging and blood testing. Systemic inflammatory response index (SIRI) were derived, and CMR parameters, including EAT volume, were measured. Cox regression analysis was used to evaluate the association between each variable and major adverse cardiovascular events (MACEs). Mediation analysis was applied to assess the interrelationships among systemic inflammatory markers, indexed EAT volume, and CMR parameters. Results: Both the SIRI and indexed EAT volume were independently associated with MACEs. Combining SIRI and indexed EAT volume significantly improved the predictive capacity for MACEs. EAT volume partially mediated the relationship between SIRI and MACEs, and similarly, SIRI partially mediated the association between EAT volume and MACEs. Additionally, we observed analogous interrelationships among SIRI, indexed EAT volume, and extracellular volume (ECV). Conclusion: In patients with CCS on long-term statin therapy, elevated SIRI and increased EAT volume represent more important risk factors than lipid levels. SIRI and EAT volume interact with each other and collectively contribute to a poor prognosis in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.